Please login to the form below
breast cancer drug
This page shows the latest breast cancer drug news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca and MSD’s breast cancer drug Lynparza receives FDA approval
An estimated 2.3 million patients were diagnosed with breast cancer in 2020. ... In the EU, this indication also includes patients with locally advanced breast cancer.
Latest news
-
Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
European patients with metastatic triple-negative breast cancer can now receive the antibody-drug conjugate as second-line monotherapy. ... Effective treatment options are extremely limited in TNBC compared with other breast cancer types and the chance
-
Aspirin to be trialled as part of new treatment for triple negative breast cancer
year. As part of the programme, Pfizer has provided an independent medical research grant to Breast Cancer Now. ... We hope our trial will show that, when combined with immunotherapy, aspirin can enhance its effects and may ultimately provide a safe new
-
NICE approval for Lilly's Verzenios is “fantastic news for thousands of women”
NICE declares Lilly’s breast cancer drug to be cost-effective, allowing routine use on the NHS. ... The drug is already approval on the NHS for previously untreated, hormone-receptor positive, HER2-negative, locally advanced or metastatic breast cancer.
-
Positive results for AZ, Merck & Co’s Lynparza in early breast cancer presented at ASCO
Lynparza became the first drug in the PARP inhibitor class to be approved in BRCA-positive breast cancer previously treated with chemotherapy in 2018. ... With AZ/Merck &Co already working with regulators to bring Lynparza to the market, a potential
-
AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
in a group of heavily pre-treated triple negative breast cancer (TNBC) patients. ... In December 2019, Enhertu won approval from the US Food and Drug Administration for metastatic HER2-positive breast cancer patients who have previously been treated
More from news
Approximately 1 fully matching, plus 221 partially matching documents found.
Latest Intelligence
-
Surviving cancer: a new era for patients
Trastuzumab successfully reduced the aggressiveness of breast cancer cells, helping to improve the lives of those suffering with the condition. ... This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer.
-
20 for 2020 – Five pharma leaders to watch in 2020
and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab. ... to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance
-
Can protein degraders unlock ‘undruggable’ drug targets?
keep it inhibited – and which also run the risk of cancer cells acquiring resistance by developing receptor mutations. ... this way. AstraZeneca’s injectable drug Faslodex (fulvestrant) for breast cancer has been approved since 2002, and acts by
-
20 for 2020 – Five pharma companies to watch
The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer therapy Herceptin (trastuzumab) with a cell-killing chemotherapy component designed to improve its ability ... Moreover, they think there
-
Integrating electronic health records into clinical trials
At the Leveraging EHR for Clinical Research Now! event, leaders from academia, companies including Amgen and AstraZeneca and the US Food and Drug Administration sought to identify the factors that are ... Pfizer, for example, won an expanded FDA label
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Roche names John Reed as new head of early research
investigational medicines, such as breast cancer drug T-DM1.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Lighthouse Medical Communications US continues its expansion with two new hires to its client services team
After graduation, Danni interned at Novartis Pharmaceuticals on the marketing and commercial team, working on the launch of their metastatic breast cancer drug.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- First evidence-based guide launched to put patients at heart of digital innovations
- Roche shares new positive Ocrevus data for MS patients
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- A creative awakening – how pharma is bringing innovation to the patient journey
- Country report: The healthcare market in South Korea
- European Commission approves potential new treatment for Pompe disease
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
